Deuruxolitinib + Placebo
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Alopecia Areata
Conditions
Alopecia Areata
Trial Timeline
Aug 5, 2025 → May 1, 2028
NCT ID
NCT07133308About Deuruxolitinib + Placebo
Deuruxolitinib + Placebo is a phase 3 stage product being developed by Sun Pharmaceutical for Alopecia Areata. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07133308. Target conditions include Alopecia Areata.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07133308 | Phase 3 | Recruiting |
Competing Products
20 competing products in Alopecia Areata
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Baricitinib | Eli Lilly | Phase 2 | 52 |
| CTP-543 | Sun Pharmaceutical | Phase 2/3 | 65 |
| CTP-543 | Sun Pharmaceutical | Phase 3 | 77 |
| Baricitinib + Placebo | Eli Lilly | Phase 2/3 | 65 |
| Baricitinib 4 MG Oral Tablet | Eli Lilly | Approved | 85 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 77 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 77 |
| minoxidil | Johnson & Johnson | Phase 3 | 77 |
| 5% Minoxidil + 2% Minoxidil | Johnson & Johnson | Phase 3 | 77 |
| Minoxidil + vehicle of 5% Minoxidil topical foam | Johnson & Johnson | Phase 2 | 52 |
| 5% Minoxidil Topical Foam + Vehicle Topical Foam | Johnson & Johnson | Phase 3 | 77 |
| Upadacitinib + Upadacitinib Placebo | AbbVie | Phase 3 | 77 |
| Upadacitinib + Placebo | AbbVie | Phase 3 | 77 |
| Secukinumab + Placebo | Novartis | Phase 2 | 52 |
| Daxdilimab | Amgen | Phase 2 | 51 |
| Ritlecitinib | Pfizer | Pre-clinical | 22 |
| LITFULO | Pfizer | Pre-clinical | 22 |
| Ritlecitinib | Pfizer | Pre-clinical | 22 |
| Ritlecitinib higher dose + Ritlecitinib lower dose + Placebo | Pfizer | Phase 3 | 76 |
| Ritlecitinib | Pfizer | Pre-clinical | 22 |
Other Products from Sun Pharmaceutical
Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85